News - The Clinic of Change

News

"MarketWatch": Kentucky State Pumps $42 Million Into Psychedelic Research

The state of Kentucky joins the growing number of regions that are investing in psychedelics, injecting tens of millions of dollars into research into the therapeutic potential of psychedelics for substance use disorders.

"The New York Times": New study demonstrates ketamine's potential in treating treatment-resistant depression

The anesthetic ketamine is a promising alternative to electroconvulsive therapy, currently one of the fastest and most effective therapies for patients with resistant depression. The study is the largest direct comparison between the two treatments.

"NIDA": U.S. Government Announces $1.5 Million in Funding for Psychedelic Medicine

“Sapo”: Psychedelics. “The risk of a person becoming dependent on the substance used in treatment is very low.”

Ketamine, which has antidepressant and anxiolytic properties, is predominantly used, with solid scientific evidence collected over the last few decades.

"Marie Claire": I used ketamine to treat depression and regained my will to live.

This anesthetic is indicated for cases that are resistant to conventional medications.

"European Medicines Agency": A Second Chance for Psychedelics

The European Medicines Agency recognizes that psychedelic-assisted therapy is promising for dealing with various mental health conditions.

"Financial Times": U.S. clinic offers ketamine therapy to treat alcoholism.

A Awakn, empresa britânica de biotecnologia, licencia medicamento para clínicas de tratamento de adicções.

"Psychedelic Health": Ketamine for Alcohol Dependence Receives Innovation Passport in the United Kingdom

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has awarded Awakn Life Sciences an Innovation Passport for its patented Ketamine-Assisted Psychotherapy for the treatment of Severe Alcohol Use Disorder.